Original filing text · Part II

Item 1 — Legal Proceedings

Myriad Genetics, Inc. · 10-Q · Q2 FY2026 · Period ended Jun 30, 2026

This is the extracted source text from the SEC filing. Formatting may differ from the original document.

For information regarding certain current legal proceedings, see Note 12, "Commitments and Contingencies" in the Notes to Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q. 29 Table of Contents